A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26. Issue 42 (6th October 2022)

• Record Type: Journal Article
• Authors: Yu, Miao; Chi, Xin; Huang, Shiwen; Wang, Zhiping; Chen, Jie; Qian, Ciying; Han, Feng; Cao, Lin; Li, Jinjin; Sun, Hui; Zhou, Lizhi; Li, Tingting; Wang, Yingbin; Zheng, Qingbing; Yu, Hai; Zhang, Jun; Xia, Ningshao; Li, Shaowei; Gu, Ying
• Is Part Of: Vaccine. Volume 40:Issue 42(2022)
• Page Start: 6141
• Page End: 6152
• Publication Date: 2022-10-06
• Subjects: Human papillomavirus -- Virus-like particle -- Triple-type vaccine -- Neutralizing antibody; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.09.010
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Persistent infection of high-risk human papillomavirus (HPV) is a leading cause of some cancers, including cervical cancer. However, with over 20 carcinogenic HPV types, it is difficult to design a multivalent vaccine that can offer complete protection. Here, we describe the design and optimization of a HPV51/69/26 triple-type chimeric virus-like particle (VLP) for vaccine development. Using E. coli and a serial N-terminal truncation strategy, we created double- and triple-type chimeric VLPs through loop-swapping at equivalent surface loops. The lead candidate, H69-51BC-26FG, conferred similar particulate properties as that of its parental VLPs and comparable immunogenicity against HPV51, −69 and −26. When produced in a GMP-like facility, these H69-51BC-26FG VLPs were verified to have excellent qualities for the development of a multivalent HPV vaccine. This study showcases an amenable way to create a single VLP using type-specific epitope clustering for the design of a triple-type vaccine.